Jeffrey S Farrow, who serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals (NASDAQ: TARS), reported the sale of 6,430 shares of the company’s common stock in a Form 4 filing with the Securities and Exchange Commission. The trades were carried out over three days - March 17 through March 19, 2026 - and generated aggregate proceeds of $439,566.
The filing breaks down the sales as follows: 2,111 shares were sold on March 17 at $69.42 per share; 2,133 shares were sold on March 18 at $68.71 per share; and 2,186 shares were sold on March 19 at $67.00 per share. The price range for the transactions spanned $67.00 to $69.42.
After these transactions, the filing shows Farrow has direct ownership of 43,316 shares of Tarsus Pharmaceuticals common stock.
Context on price and valuation
At the time of reporting, Tarsus shares were trading at $66.75, which implies a market capitalization of $2.85 billion for the company. Analysis from InvestingPro included in the disclosure characterizes the stock as appearing undervalued relative to its Fair Value and places it on a Most Undervalued list of covered equities.
The company’s balance sheet was described as strong in the same analysis, noting that Tarsus holds more cash than debt and that its liquid assets exceed short-term obligations. However, the business remained unprofitable over the last twelve months.
Reason for the sales
The Form 4 indicates the stock sales were executed to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units. The filing cites the company’s mandatory sell-to-cover policy as the mechanism that required these disposals.
Recent operating performance
Tarsus also reported notable financial results for the fourth quarter of 2025, with net product sales of $151.7 million for the quarter and $451.4 million for the full year. The company’s performance in that period was led by its flagship product, XDEMVY. Despite the strong reported sales, the stock experienced a small decline in aftermarket trading, reflecting a nuanced investor reaction to the earnings release.
Investors seeking deeper examination are directed to a comprehensive Pro Research Report on TARS, which is one of the equities covered with expert analysis.